Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide Monotherapy in Wolfram Syndrome Type 1
2022-003853-70Phase 2Active
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of tirzepatide in Wolfram syndrome (WFS1), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Positive MMTT Response. Started Feb 2023; status: active.
02
Drugs
03
Conditions
Wolfram syndrome (WFS1)
Beyond the preview
Go deeper on 2022-003853-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003853-70.